

IMPORTANT:

Name of oncologist: _____

Contact number: _____

After-hours contact number: _____

My name: _____

My contact number: _____

Emergency contact: _____

Emergency contact number: _____

You should not start any other medicines during your treatment without talking to your doctor first. If you develop any signs or symptoms listed on this card or if you notice any signs or symptoms not listed on this card, please contact your doctor **immediately**. Getting medical treatment early may stop the problem from becoming more serious. If you have any further questions about your treatment or on the use of this medicine, please contact your doctor. It is important that you carry this card with you **at all times**. Please ensure you show this card to **all** Healthcare Professionals (including nurses, pharmacists and dentists), to any doctor involved in your treatment, and at any visits to the hospital.

Important information for Health Care Providers

This patient is being treated with Tecentriq® (atezolizumab), which can cause immune-related adverse reactions that involve the lungs, liver, intestines, hormone glands, heart, and other organs, as well as infusion-related reactions. Early diagnosis and appropriate management are essential to minimise any consequences of immune-related adverse reactions.

For suspected immune-related adverse reactions, ensure adequate evaluation to confirm aetiology or exclude other cause. Based on the severity of the adverse reaction, withhold Tecentriq® and administer corticosteroids. Specific guidelines for managing immune-related adverse reactions are provided in the **Summary of Product Characteristics** for atezolizumab, available at www.medicines.ie and www.ema.europa.eu.

Please contact the patient's Oncologist (details on this card) for more information.

Assess patients for signs and symptoms of pneumonitis, hepatitis, colitis, endocrinopathies (including hypophysitis, adrenal insufficiency, type 1 diabetes mellitus, hypothyroidism, hyperthyroidism), myocarditis, pancreatitis, nephritis, myositis and infusion-related reactions. Other immune-related adverse reactions reported in patients receiving atezolizumab include: neuropathies (Guillain-Barré syndrome, myasthenic syndrome/Myasthenia Gravis), and meningoencephalitis.

Please consult the Summary of Product Characteristics for Tecentriq® available at www.medicines.ie and www.ema.europa.eu.

Reporting of suspected adverse events or reactions

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions (see details below). Reporting suspected adverse events or reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Where possible, healthcare professionals should report adverse events or reactions by brand name and batch number.

In the event of a suspected adverse event, please report it to:

The Drug Surveillance Centre,
Roche Products (Ireland) Limited, 3004 Lake Drive,
Citywest, Naas Road, Dublin 24, Ireland.

Telephone: 00 353 (0)1 4690700;

Email: ireland.drug_surveillance_centre@roche.com

Alternatively, suspected adverse reactions (side effects) or medicines errors may be

reported using the Medicines Authority ADR reporting form, which is available online at:

<http://www.medicinesauthority.gov.mt/adrportal>,

and sent by post or email to:

Post: Pharmacovigilance Section at

Post-Licensing Directorate, Medicines Authority,
Sir Temi Żammit Buildings, Malta Life Sciences Park,
San Ġwann SĠN 3000, Malta.

Email: postlicensing.medicinesauthority@gov.mt

Further information

For electronic copies of this risk minimisation material, refer to the Malta Medicines Authority website [

<http://www.medicinesauthority.gov.mt/rmm>]

and download the required material. Alternatively

if you would like hard copies, please contact

Roche Products (Ireland) Limited,

3004 Lake Drive, Citywest, Naas Road, Dublin 24,

Ireland by mail, telephone (00 353 (0)1 4690700),

fax (00 353 (0)1 4690793) or email

(ireland.drug_surveillance_centre@roche.com).

For further information about this medicine,

please contact Medical Information at

Roche Products (Ireland) Limited by telephone

(00 353 (0)1 4690700), fax (00 353 (0)1 4690791)

or email (Ireland.druginfo@roche.com).



MT Version 17.1.0

Date of Malta Medicines Authority Approval: April 2021

Copyright © 2021 by Roche Products (Ireland) Limited.

All rights reserved.

FOR USE IN MALTA

Tecentriq®▼ (atezolizumab)

Patient Alert Card

Please read this material along with the Package Leaflet supplied with this medicine or also available on www.medicines.ie and www.ema.europa.eu before taking this medicine.

IMPORTANT:

Tecentriq® (atezolizumab) can cause serious side effects in many parts of your body that need to be treated right away. Symptoms may occur at any time during treatment or even after your treatment has ended. Call your doctor right away if you develop any of these new signs or symptoms listed on this card or if your symptoms should get worse. Also tell your doctor if you experience any other symptoms not listed on this card. Do not try to treat your symptoms on your own.

Carry this card with you at all times, especially when you travel, whenever you go to the Accident and Emergency department, or when you see another doctor.

Select important safety information

Serious side effects may include lung problems

(pneumonitis), liver problems (hepatitis), intestinal

problems (colitis), problems in hormone glands (for

example thyroid problems or diabetes), heart, nervous

system, and other organs. These events may result in

signs or symptoms such as:

- **Lungs:** new or worsening cough, shortness of breath, chest pain
- **Liver:** yellowing of skin or the whites of eyes, nausea or vomiting, bleeding or bruising, dark urine, stomach pain

- **Intestines:** diarrhoea (watery, loose or soft stools), blood in stools, stomach pain
- **Hormone glands:** tiredness, headache, weight loss, weight gain, change in mood, hair loss, constipation, dizziness, feeling more hungry or thirsty than usual, need to urinate more often, vision changes, increased sensitivity to cold or heat

- **Brain:** neck stiffness, headache, fever, chills, vomiting, eye sensitivity to light, confusion, sleepiness
- **Heart:** chest pain, shortness of breath, irregular heart beat, feeling tired, fainting, decreased exercise tolerance, ankle swelling

- **Musculoskeletal:** inflammation or damage of the muscles; muscle pain and weakness
- **Nerves:** muscle weakness and numbness, tingling in your hands and feet

- **Pancreas:** abdominal pain, nausea, vomiting
- **Kidneys:** changes in urine output and colour, pain in pelvis, and swelling of the body

- **Reactions associated with infusion** (during or within 1 day of infusion): fever, chills, shortness of breath, flushing

- **Reactions associated with infusion** (during or within 1 day of infusion): fever, chills, shortness of breath, flushing

- **Reactions associated with infusion** (during or within 1 day of infusion): fever, chills, shortness of breath, flushing

Getting medical treatment immediately may stop the problems from becoming serious. Your doctor may decide to give you other medicines to prevent complications and reduce your symptoms, and may withhold the next dose or stop your treatment.

IMPORTANT Reminders for Patients

Tecentriq® (atezolizumab) is a medicine to treat adults

with different types of tumours (e.g. urothelial carcinoma,

non-small cell lung cancer, small cell lung cancer,

triple negative breast cancer) as monotherapy or in

combination with other anticancer medicines.

For a complete list of current indications, please refer to the Tecentriq Package Leaflet available at www.medicines.ie and www.ema.europa.eu. Like all medicines, Tecentriq® (atezolizumab) may cause side effects, although not everybody gets them. It is important to tell your doctor **immediately** if you develop any of the signs or symptoms listed on this card after starting treatment with atezolizumab.

Before you start atezolizumab or during your treatment, you should also tell your doctor immediately if you:

- Have an autoimmune disease (a condition where the body attacks its own cells, examples include autoimmune thyroid disease, systemic lupus erythematosus (SLE), Sjogren's syndrome, multiple sclerosis, rheumatoid arthritis, vasculitis, glomerulonephritis)
- Have been told that your cancer has spread to your brain

- Have any history of inflammation of your lungs (pneumonitis)
- Have or have had chronic viral infection of the liver, including hepatitis B (HBV) or hepatitis C (HCV)

- Have human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS)

- Experienced serious side effects because of other antibody therapies that help your immune system to fight cancer

- Have been given medicines to stimulate your immune system such as interferons or interleukin-2 as these medicines may worsen the side effects of atezolizumab

- Have been given medicines to suppress your immune system such as corticosteroids, since these medicines may interfere with the effect of atezolizumab

- Have been given a live, attenuated vaccine such as influenza intranasal vaccine, yellow fever vaccine

Reporting of side effects

▼ This medicine is subject to additional monitoring.

This will allow quick identification of new safety

information. You can help by reporting any side

effects you may get. If you experience any side

effects, talk to your doctor, pharmacist or nurse.

This includes any possible side effects not listed in

the package leaflet. You can also report side effects

directly (see details below).

Please report it to:

Post: The Drug Surveillance Centre,

Roche Products (Ireland) Limited, 3004 Lake Drive,

Citywest, Naas Road, Dublin 24, Ireland.

Telephone: 00 353 (0)1 4690700;

Email: ireland.drug_surveillance_centre@roche.com

Alternatively, side effects may be reported using the Medicines Authority ADR reporting form, which is available online at:

<http://www.medicinesauthority.gov.mt/adrportal>,

and sent by post or email to:

Post: Pharmacovigilance Section at

Post-Licensing Directorate, Medicines Authority,

Sir Temi Żammit Buildings, Malta Life Sciences Park,

San Ġwann SĠN 3000, Malta.

Email: postlicensing.medicinesauthority@gov.mt

Further information

Please read the atezolizumab (Tecentriq®) package

leaflet for further information on this medicine. Talk

to your doctor, nurse or pharmacist if you have any

questions or concerns.